Open AccessComparison of the effect of recombinant human pro-urokinase and tirofiban on myocardial blood flow perfusion in ST elevation myocardial infarction patients receiving primary percutaneous coronary intervention
Author(s) -
Zhuhua Yao,
Wenting Li,
Lisong Cheng,
Mingying Cao,
Zhihua Pang,
Yongbin Li
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016143
Subject(s) - medicine , tirofiban , cardiology , myocardial infarction , percutaneous coronary intervention , perfusion , blood flow , thrombolysis , urokinase
Ischemia/reperfusion (I/R) injury is associated with primary percutaneous coronary intervention (PPCI). The current study was performed to compare the effect of tirofiban and recombinant human pro-urokinase (rh-proUK) on the improvement of coronary slow blood after PPCI. Sixty-five ST elevation myocardial infarction (STEMI) patients treated with rh-proUK and an equal number treated with tirofiban after PPCI were employed in the current study. The clinicopathological information regarding the biochemical parameters, thrombolysis in myocardial infarction (TIMI) grade, hemodynamics parameters, thrombus core (TS), sum-STR, left ventricular ejection fraction (LVEF), blood routine parameters, high-sensitivity C-reactive protein (CRP) level, uric acid, hepatorenal function, electrocardiogram (ECG), and echocardiography before and after the interventions were collected. The differences in those parameters between the 2 groups then compared with assess the treatment effect and side effects associated with the both therapies. The results showed that the TIMI level post-intervention ( P = .03), the proportion of TIMI myocardial perfusion grade level III ( P = .04), the changes in thrombus score ( P < .001) in rh-proUK group were significantly higher than those in tirofiban group while the corrected TIMI Frame Count (CTFC) ( P = .02), the incidence of slow flow ( P = .02), the thrombus score post-intervention ( P < .001), the stent length ( P = .02), and the number of receiving administration of sodium nitroprusside ( P = .01) were significantly lower than those in tirofiban group. Moreover, the levels of CK ( P < .001), CK-MB ( P = .01), and NT-proBNP 24-hour post-intervention ( P < .02) were significantly lower in rh-proUK group than those in tirofiban group and the sum-STR right after the intervention ( P < .03) of rh-proUK group was significantly higher than that of tirofiban group. No significant difference was detected between the 2 therapies regarding major adverse cardiac events (MACE). The findings outlined in the current study showed that the improvement effect of rh-proUK on blood flow condition was stronger right after the intervention and the therapy had a similar safety when compared with tirofiban during a 30-day follow-up.